The complex molecular landscape of Her2 alteration has probably confounded previous clinical trials of Her2-targeted therapies, and improved patient selection accounting for multi-modal Her2 status and tumor molecular subtype will be essential for future clinical trial design. This evidence concerns the gene ERBB2 and neoplasm.